Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Dec 20;6:39534. doi: 10.1038/srep39534

Compound to Extract to Formulation: a knowledge-transmitting approach for metabolites identification of Gegen-Qinlian Decoction, a traditional Chinese medicine formula

Xue Qiao 1, Qi Wang 1, Shuang Wang 1, Wen-juan Miao 1, Yan-jiao Li 1, Cheng Xiang 1, De-an Guo 1, Min Ye 1,a
PMCID: PMC5171860  PMID: 27996040

Abstract

Herbal medicines usually contain a large group of chemical components, which may be transformed into more complex metabolites in vivo. In this study, we proposed a knowledge-transmitting strategy for metabolites identification of compound formulas. Gegen-Qinlian Decoction (GQD) is a classical formula in traditional Chinese medicine (TCM). It is widely used to treat diarrhea and diabetes in clinical practice. However, only tens of metabolites could be detected using conventional approaches. To comprehensively identify the metabolites of GQD, a “compound to extract to formulation” strategy was established in this study. The metabolic pathways of single representative constituents in GQD were studied, and the metabolic rules were transmitted to chemically similar compounds in herbal extracts. After screening diversified metabolites from herb extracts, the knowledge was summarized to identify the metabolites of GQD. Tandem mass spectrometry (MSn), fragment-based scan (NL, PRE), and selected reaction monitoring (SRM) were employed to identify, screen, and monitor the metabolites, respectively. Using this strategy, we detected 131 GQD metabolites (85 were newly generated) in rats biofluids. Among them, 112 metabolites could be detected when GQD was orally administered at a clinical dosage (12.5 g/kg). This strategy could be used for systematic metabolites identification of complex Chinese medicine formulas.

Traditional Chinese medicines (TCM) usually contain a large group of chemical components. These components may act synergistically to improve the therapeutic effects or independently to deal with different symptoms1,2. Meanwhile, phytochemicals and their in vivo metabolites may have comparative chances to exhibit the therapeutic effects3. Therefore, the metabolites could be critical to the bioactivities of TCM, and required unbiased elucidation.

Analytical chemists have made a lot of efforts to identify the metabolites of complex mixtures including TCM. Technologies including UPLC/SRM-MS and LC-NMR-MS significantly improved the detection sensitivity4,5, while several strategies emerged to predict and identify herbal metabolites globally. These strategies could be categorized into chemistry-based and exposure-based. The former one identified metabolites based on the chemistry of herbal medicine or prescription. For instance, Li et al. used seven LC/MS conditions to identify 28 catechols in DanHong Injection, and monitored their contents in volunteers6. Similarly, Wang et al. employed a UPLC-qTOF-MS/MS pharmacokinetics (PK) method to screen the absorbed components in Yin-Chen-Hao-Tang, a three-herb formula. They successfully monitored the PK of 21 compounds in rats plasma, and elucidated possible bioactive components by using hierarchical cluster analysis7. In these strategies, the biotransformed metabolites received less attention than the prototypes. The exposure-based strategies intended to systematically identify herbal compounds and their metabolites simultaneously. For instance, Gong et al. studied the metabolic network of TCM, and the possible relationship between original form and their metabolites8. Chen et al. identified 55 prototype compounds and 39 metabolites of Si-Ni Decoction in vivo9. Such strategies were unbiased, but might miss part of the metabolites.

Gegen-Qinlian Decoction (GQD) is a famous TCM formulation firstly recorded in the TCM ancient classic Shang-Han-Lun (Treatise on Febrile Diseases) of Han Dynasty (202 BC-220 AD). It is composed of four herbs, Puerariae Lobatae Radix (P), Scutellariae Radix (S), Coptidis Rhizoma (C), and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle (G) in the ratio of 8:3:3:2 (w/w/w/w)10. According to the TCM formulation theory, P is the emperor herb of the formula playing the major therapeutic role. S and C are the minister herb, and G is the adjuvant and guide herb to harmonize the characteristics of other herbs to achieve optimal therapeutic effects and to reduce potential side effects. GQD is currently used in clinical practice to treat diarrhea11. More than 200 compounds have been reported from the four component herbs of GQD, thus far, including flavonoids (from P, S, and G), alkaloids (from C), and triterpenoid saponins (from G)12,13,14,15. Recently, We have identified 138 chemical constituents from GQD using 2D-LC/MS, and have determined the contents of 50 compounds in GQD and its patent drugs16,17. However, only a few reports are available on the metabolism of GQD. Hou et al. monitored the plasma concentrations of 10 phytochemicals and 6 phase II metabolites for decoction and concentrated powder of GQD18. We had also investigated the metabolites of GQD, and identified 42 in vivo metabolites (21 of them were detected in plasma)19. The in vivo exposed metabolites of GQD were not systematically characterized given its complex chemical composition.

In our previous report, we had developed a “compound to extract” strategy to comprehensively characterize the metabolites of licorice water extract20, and monitored the PK of 55 licorice compounds and metabolites in rats21. It used the metabolic route of representative single compounds to predict and identify the metabolites of other compounds. In the present study, we intend to improve this strategy so that it is compatible with the more complex formula GQD. As depicted in Fig. 1, firstly, we use tandem mass spectrometry (MSn) to study the metabolic rules of 19 representative compounds (eight groups with different scaffolds). Secondly, we use neutral loss scan (NL) and precursor ion scan (PRE) of LC/MS/MS analysis to systematically characterize the metabolites of each component herb. Finally, the identified metabolites are confirmed by qTOF-MS, and then detected by the sensitive SRM scan mode of LC/MS/MS. By following this strategy, we detected 131 metabolites (including 46 original phytochemicals and 85 newly formed ones) in rats after a single dose oral administration of GQD. Among them, 112 metabolites could be detected at a clinical dosage (12.5 g/kg). Furthermore, parent compounds for the detected metabolites were interpreted.

Figure 1. Knowledge-transmitting strategy of the study.

Figure 1

Open in a new tab

Results

Metabolic pathways of representative single compounds

In our previous study, we selected 10 representative compounds from licorice, elucidated their metabolic rules, and used these rules for metabolite identification of other compounds which have the similar scaffolds in licorice extract, developing a “compound to extract” strategy20. In the present study, this strategy was extrapolated to the four-herb formulation GQD. Chemical constituents in GQD could be classified into eight groups according to their structural type: flavonoid C-glycosides (A), flavonoid O-glucuronides (B), benzylisoquinoline alkaloids (C), free flavonoids (D), flavonoid O-glycosides (E), coumarins (F), triterpenoid saponins (G), and other atypical and abundant backbones (H). Among them, groups D, E, F and G had been investigated in our previous studies on licorice20,21. The metabolic pathways of flavonoid C-glycosides, O-glucuronides, and alkaloids were reported in this paper. In total, 19 single compounds were selected to represent seven major scaffolds in GQD. These compounds were labeled in the HPLC fingerprint of GQD (Fig. 2).

Figure 2. HPLC fingerprints of GQD and its component herbs, showing the single compounds selected for metabolic studies.

Figure 2

Open in a new tab

P, Puerariae Lobatae Radix; S, Scutellariae Radix; C, Coptidis Rhizoma; G, Glycyrrhizae Radix et Rhizoma Praeparata cum Melle. UV wavelength of P, S, C, G and GQD were 254 nm, 270 nm, 270 nm, 300 nm, and 270 nm, respectively. Black arrows show representative compounds.

Flavonoid C-glycosides ( A )

Pueraria compounds P2, P9 and P10 were chosen as representatives of this type (Fig. 3). They were abundant in Puerariae Lobatae Radix, and were considered as its characteristic and bioactive constituents12. C-glycosides could lose the sugar residue to produce corresponding aglycones, which is difficult for chemical hydrolysis. As shown in Fig. 4, P2, P9 and P10 could be metabolized into 3′-methoxydaidzein, daidzein and 3′-hydroxydaidzein, respectively. This reaction was also observed for isoflavone C-diglycoside (P6) and flavone C-diglycoside (S4 from Scutellariae Radix). This C-glycosidic bond cleavage reaction was firstly reported by Prasain et al. and was attributed to microbial metabolism in the intestine, albeit the catalyzing microbial strain is still unknown22. S4 contains both 6-C-arabinoside and 8-C-glucoside. Only the latter was de-conjugated in vivo. The preference could be oriented either by saccharide type or by substitution position. We considered the latter one more reasonable, since both 6-C-glc and 8-C-glc had been reported for de-conjugation in vivo23.

Figure 3. Compounds isolated from Gegen-Qinlian-Decoction (GQD).

Figure 3

Open in a new tab

Figure 4. Metabolic pathways of flavonoid C-glycosides P2, P9 and P10.

Figure 4

Open in a new tab

Metabolites were identified by authentic reference compounds before (*) or after (**) β-glucuronidase hydrolysis.

Reactions on the backbone were also observed. When the 3′-carbon was substituted, the 3′-OH (3′-methoxydaidzein) and 3′-OCH3 (3′-hydroxydaidzein) isoflavones could be transformed into each other, while the 3′-H isoflavone (daidzein) could be reduced to S-equol (P5). Phase II conjugation reactions (to form glucuronides and sulfates) were common for C-glycosides. However, when the glycosides were hydrolyzed into corresponding aglycones, phase II metabolites occurred only on daidzein (P9). We speculate that the 3′-H, 4′-OH substitutions may play an important role24. Metabolites identified from the three Pueraria compounds were listed in Table 1S. Plasma and feces samples mainly contained phase II metabolites and aglycones, respectively, while urine samples covered most metabolites.

Flavonoid C-glycosides produced characteristic fragments in (−)-ESI-MS. The C-glycosides cleaved to produce neutral loss of C4H8O4 (120 Da) and C3H6O3 (90 Da). Aglycone fragments m/z 295, 311, and 325 were produced for P9, P10 and P2, after eliminating 120 Da. The aglycone could be cleaved on C-ring to produce m/z 253, 269, and 283, respectively. Phase I metabolites of Pueraria compounds underwent minor modification on their aglycones, and produced fragment ions that were close to the parent compounds, e.g. m/z 241, 257, and 267. Phase II metabolites mainly undertook neutral losses of glucuronide (NL 176) and sulfate (NL 80)12,19,25. Typical MS/MS fragmentations are shown in Fig. 5. PRE and NL ions were then selected from diagnostic fragments (labeled in red and blue, respectively), as listed in Table 1.

Figure 5.

Figure 5

Open in a new tab

Neutral loss scans (mass value in blue) and precursor ion scans (m/z in red) established from predicted (A) and unpredicted (B) metabolites for Puerariae Lobatae Radix.

Table 1. Eight types of major chemical constituents in GQD. The representative compounds, original herb, MS behavior in NL and PRE scans, major in vivo metabolic reactions, and distribution.

  Structural type Compound Herba Neutral loss scanb (m/z) Precursor ion scan (m/z) Supplementary precursor ion scan (m/z) Metabolic reactionc Distributiond (P/U/F)
A Flavonoid C-glycoside P2, P9, P10 P, S 15, 28, 120, 176, 252# 119, 135, 225, 241, 253, 257, 267, 283, 295, 311, 321, 325, 333, 415, 417, 430, 431, 445 149, 268, 269, 297, 309, 429, 461 H/S/G deM/M (C3′) RC (C-ring) P/MP/MIP
B Flavonoid O-glucuronide S14, S15, S17 S 15, 18, 28, 80, 90, 120, 162, 176, 210 119, 241, 268, 269, 283, 295, 325, 385, 427, 431, 457, 459 101, 125, 151, 175, 177, 253, 285, 299, 301, 303, 330, 345, 349, 401, 425, 429, 445, 475 H/G/Glc deM/M (C6,7) C-ring stable MP/MP/MAP
C Benzylisoquinoline alkaloid C1, C2 C 15, 18, 45#, 176 (+) 295, 307, 308, 309, 321, 322, 323, 324, 337, 338, 484 (+) 292, 297, 340, 342, 354, 358, 372 (+) deM/M/OH G T/M/T
D Flavonoid aglycone Supplementary NL/PRE feature  
   D1 Isoflavone G17 G, P P17, P18, P3 NL CO2, CO, CH3,H2O, G, S, etc.Common PRE not available. deM/M, RC, S/G MP/MP/P
   D2 Flavone G3 G, S S2, S3, S10 deM/M, G T/M/P or T
   D3 Flavanone G10 G G4, G1 RC, RH, S/G MP/M/MIP
   D4 Chalcone G8 G G5, G2 RC, RH, S/G MP/M/MIP
E Flavonoid O-glycoside Supplementary NL/PRE feature  
    mono-O- G1, G2 G, P P1, P4 NL/PRE: G/A H/S/G, RC MP/MP/MAP
    di-O- G4, G5 G, P P6 NL/PRE: G/A H/S/G, RC MP/MP/MAP
F Coumarin G11 G   NL G, S, CO2 OH/OdeH, S/G MP/MP/P
G Saponin G6 G   NL/PRE: A/G H, G, OH MP/MP/A
H Atypical, abundant backbones Initiate Confirm New scan  
   pueroside P12 P NL 80, 176 EIC/PROD 391, 487 PRE 311 Unstable, H/S/G M/M/T
   flavanonol S1 S NL 176 EIC/PROD 477, 479 PRE 301, 303 OdeH, S/G MII/MP/P
   phenylethanoid glycoside S17 S NL 162 EIC/PROD 623 PRE 461 Unstable T/M/T
   aporphine alkaloid C6 C NL 176, 18 (+) EIC/PROD 342 (+) NL 45 (+) deM/M/OH, G T/M/T
   flavonol S7 S NL 80 EIC/PROD 345 PRE 431 RH, S/G MII/M/P
Open in a new tab

aOrigin: P, Puerariae Lobatae Radix; S, Scutellariae Radix; C, Coptidis Rhizoma; G, Glycyrrhizae Radix et Rhizoma Praeparata cum Melle.

bMS scan mode: NL, neutral loss scan; PRE, precursor ion scan; PROD, product ion scan; EIC, extracted ion current; (+) determined in (+) ESI mode; data were obtained in (−) ESI mode unless otherwise stated; Scans marked with # were newly established from MS screening process.

cMetabolic reaction: G, glucuronidation; H, hydrolysis; M, methylation; deM, demethylation; OH, oxidation (hydroxylation); OdeH, oxidation (dehydrogenation); RH, reduction (hydrogenation); RC, ring cleavage; S, sulfation.

dDistribution, P, plasma; U, urine; F, Feces. Analyte type: M, metabolite; MI, phase I metabolite; MII, phase II metabolite; MA, metabolite formed by hydrolysis, namly aglycones; P, prototype (unchanged form) T, trace or low abundance.

Flavonoid O-glucuronides ( B )

Occurrence of O-glucuronides is less common in plants. Flavonoid glucuronides in GQD are all derived from Scutellariae Radix, where they were considered as characteristic components13. Three major ones (S14, S15, S16) were chosen to study their in vivo metabolism. They underwent hydrolysis in gut, which allowed the absorption of their prototype and aglycone simultaneously. After absorption, aglycones will rapidly conjugate with endogenous glucuronic acid. Thus the interconversion between glucuronides and their aglycones became the major metabolic pathway of Scutellaria O-glucuronides26,27,28. Aside from the interconversion, glucuronide relocation in this study was also a major reaction. For S15 and S16, isomers of the parent drug were detected, and their aglycones remained unchanged, as confirmed by β-glucuronidase hydrolysis. Hence, we proposed that the glucuronide group was hydrolyzed during absorption, and the in vivo conjugation occurred at a different position. We speculate that the glucuronide group was relocated from C-7 to C-5 for S15 (5-OH, 8-OCH3), and from C-7 to C-6 for S16 (5-OH, 6-OH), according to previous report29. Several glucuronide conjugates have now been proved for bioactivities, including wogonoside (S15) baicalin (S16), and scutellarin (S13)27,28. Changes in substitution positions may alter the bioactivity of the parent drug. Although glucuronidation occurred readily, sulfate products were rarely detected. Metabolic pathways of these three compounds are shown in Fig. 6.

Figure 6. Metabolic pathways of flavonoid O-glucuronides S14, S15 and S16.

Figure 6

Open in a new tab

Metabolites were identified by authentic reference compounds before (*) or after (**) β-glucuronidase hydrolysis.

Other metabolic reactions for glucuronides included methylation/demethylation at C-6 and C-8, and glycosidation on the backbone26. For example, S16 could produce glycoside SS21 (m/z 431→269, 197, identified as baicalein-O-glc) and glucuronide-conjugated glycoside SS10 (m/z 607→431→269, identified as baicalein 7-O-glc-O-gluA). These metabolites were detected in urine and plasma, and the unconjugated form of SS10 was confirmed as baicalein-7-O-glucoside (Fig. 6). Glycosidation is a rare in vivo reaction, and was reported to be catalyzed by human liver microsomes30. Metabolites derived from the three Scutellaria compounds were listed in Table 2S.

Flavonoid O-glucuronides yielded similar MS fragments (NL 176) as their metabolites Besides, flavones, flavanonols and flavonols showed various fragmentation pathways, which could be explained according to previous studies14,19,31. Characteristic fragments were summarized for Scutellaria compounds (Fig. 7). Although MS behaviors are similar for natural glucuronides and their metabolites, natural products haveve unique substitution at the C-7 position, while in vivo metabolites generally contain C-5 gluA substitution. These isomers could be separated by HPLC. Based on the MS fragmentations, NL and PRE scan channels for metabolites screening were listed in Table 1.

Figure 7.

Figure 7

Open in a new tab

Neutral loss scans (mass value in blue) and precursor ion scans (m/z in red) established from predicted (A) and unpredicted (B) metabolites for Scutellariae Radix.

Benzylisoquinoline alkaloids ( C )

More than 10% (w/w) of Coptidis Rhizoma crude drug was benzylisoquinoline alkaloids14. Their distribution and metabolism had been reported in several different organisms32,33,34,35,36. We chose palmatine (C1) and berberine (C2) for metabolic studies. C2 was found poorly exposed in plasma. Due to lack of free hydroxyl group, C2 was destined to be deduced (C-2, C-3) or demethylated (C-9, C-10) to form free hydroxyl groups, which then underwent phase II metabolism36. C2 was mainly eliminated from urine, and the metabolic pathway is shown in Fig. 1S. Among multiple metabolites, CS13 (C-10 demethylation), CS15 (C-9 demethylation) and CS8 (glucuronide of CS15) were the major products33. C1 exhibited higher plasma exposure than C2. The methoxyl groups at C-2, 3, 9 and 10 underwent multiple demethylation, followed by glucuronide conjugation34. Metabolites identification for Coptidis alkaloids were listed in Table 3S. They produced one or multiple common small fragments like H2O, CH3, and C2H6N, respectively, and were monitored in the (+)-ESI mode (Fig. 8). Their NL and PRE scans were also preformed in the (+)-ESI mode.

Figure 8.

Figure 8

Open in a new tab

Neutral loss scans (mass value in blue) and precursor ion scans (m/z in red) established from predicted (A) and unpredicted (B) metabolites for Coptidis Rhizoma.

Free Flavonoids ( D )

Free flavonoids have complex group members which could be further divided into isoflavones (D1), flavones (D2), flavanones (D3), and chalcones (D4). Their metabolism had been studied in our previous report on licorice20, represented by compounds G18, G3, G10 and G8, respectively. Sub-groups D1 to D4 cover major aglycone structures in GQD, and their metabolic pathways could also be supplemented by corresponding glycosides P2, P9, P10 (aglycones P18, P3, P17 belong to D1), S14, S15, S16 (aglycones S3, S2, S10 belong to D2), G4, G1 (aglycone G10 belongs to D3), and G5, G2 (aglycone G8 belongs to D4).

In brief, metabolism of free flavonoids varies according to the substitution on the backbones. For example, daidzein (P3, the aglycone of P9) from Pueraria could undertake different phase I reactions, including methylation, reduction, and C-ring cleavage. The metabolites were identified as 3′-methoxydaidzein (P18), formononetin (P20), and O-desmethylangolensin (P7), respectively, which could be further metabolized into phase II conjugates (Fig. 4). Flavones from Scutellaria were mainly involved in (de)methylation and phase II metabolism. Therefore, besides neutral loss of common phase II metabolites (glucuronide and sulfate), common fragments in the flavonoid backbones (CO2, CO, CH3, and H2O) were set for further metabolites screening.

Flavonoid O-glycosides ( E ), coumarins ( F ), and triterpenoid saponins ( G )

Flavonoids and saponins were major constituents of licorice. Our previous studies elucidated metabolism of 11 single compounds20,21. These compounds were labeled in Fig. 3. Briefly, major metabolic reactions for types E, F, and G were de-glycosidation, phase II conjugation, and de-glucuronidation, respectively. For example, P1 (daidzin, daidzein 7-O-glucoside) was rapidly hydrolyzed into daidzein (P3) following absorption24,37. Flavonoid O-glycosides and triterpene saponins underwent hydrolysis after oral administration to produce corresponding aglycones. Flavonoids were eliminated more rapidly than saponins21. Similar to Scutellaria glucuronides, flavonoid O-glycosides could produce neutral loss fragment of glycoside (162 Da), and precursor ions of [A-H]− (A = aglycone) in the negative ion mode. Notably, saponins behaved oppositely in CID, where the aglycone fragment (e.g. 470 Da for G6) was neutral while the saccharide chain (m/z 351) was charged. Coumarins could uniquely lose the CO2 group (44 Da). These fragments were considered as characteristic NL/PRE ions, and were used in metabolites screening of GQD.

Atypical and abundant backbones ( H )

Besides major structural types (A) to (G), atypical structures were also found in GQD, according to previous chemical studies19. They were also taken into consideration in our study, using the metabolite screening method. Representative scaffolds include flavanonol (S1, 3,5,7,2′,6′-pentahydroxyflavanone), phenylethanoid glycosides (S17, acteoside), puerosides (P12, sophoraside A), aporphine alkaloids (C6, magnoflorine), and flavonols (S7, viscidulin III). Metabolites identification of S1, C6, S17, P12 were depicted in Fig. 9. In general, metabolites through a common pathway were discovered by NL scans (80, 176 and 162 Da). These metabolites were screened to rule out false positive by a complementary EIC scan (e.g. EIC 477, 479, and EIC 623, respectively), and were identified by corresponding PRE scan (m/z 311, m/z 301, 303 and m/z 299, respectively). For the aporphine alkaloid C6, common NL scan of 176 Da (m/z 518) obtained signals at around 14 min. However, the other common NL (18 Da, H2O) of alkaloid did not respond to this signal compared with benzylisoquinoline alkaloids, suggesting minor differences in the structure. The metabolite was finally identified as magnoflorine glucuronide. The parent compound was confirmed by enzyme hydrolysis and authentic reference compounds. Metabolite identification of S7 using the similar method is described in the following section. For the eight atypical scaffolds, major NL/PRE scans, major metabolic reactions and metabolite distributions were summarized as in Table 1.

Figure 9. Metabolites identification of P12(i), S1(ii), S17(iii), and C6(iv) using NL and PRE scans.

Figure 9

Open in a new tab

Metabolism of herbal extracts

Based on the fragmentation pathways summarized from representative single compounds, NL and PRE scans were established to search for conjugation groups and aglycone groups, respectively38,39. These scans were used to confirm identified metabolites and to discover new metabolites as a complementary method. By the scanning of familiar conjugates, unfamiliar aglycones might be exhumed, and vice versa. Once an unfamiliar aglycone was found, a new PRE scan would be established to search for its metabolites. Workflow of this step was depicted in Fig. 10. For the component herb Scutellariae Radix, 18 PRE scans were newly established for Scutellaria compounds following the above strategy. In total 30 PRE scans and 9 NL scans allowed the identification of 56 metabolites, after an oral administration of Scutellariae Radix extract (Table 4S). Here we take viscidulin III-O-sulfate (SE24, SE44) as an example to elucidate the process. Firstly, according to the diagnostic ions for A to H (Fig. 7), NL 80 and PRE 431 were used to analyze rats plasma samples. A number of metabolites could be detected by NL 80 (Fig. 10), and their charged fragments (aglycones) could be calculated as [M-H-80]−, where [M-H]− was the parent ion detected in neutral loss scan.

Figure 10. Workflow (top) and an example (bottom) for metabolites screening in herbal extracts.

Figure 10

Open in a new tab

Therefore, the charged aglycone of an m/z 511 metabolite (RT = 58.4) was calculated as m/z 431. The signal was in accordance with the PRE 431 scan, where the peak m/z 511 was detected at the same retention time (Fig. 10). The metabolite was identified as baicalein-O-glc-O-sulfate (SE40) based on the studies of single compounds. At the same time, a pair of m/z 425 signals (RT = 43.6, 59.1) was detected by NL 80, suggesting their charged aglycone as m/z 345. Therefore, a PRE m/z 345 scan was newly established, from which the corresponding signals were found (RT = 43.6 min, 59.1 min). Meanwhile, a group of phase II conjugates derived from m/z 345 were detected (Fig. 11). These conjugates could be degraded by β-glucuronidase, producing a single aglycone, which was identified as viscidulin III by comparing with a reference standard. According to the correspondence of NL 80 and PRE 345, SE24 and SE44 were identified as viscidulin III-O-sulfates. Other metabolites were identified as viscidulin III-O-GluA-O-Sul (SE10) and viscidulin III-O-GluA (SE12, SE16). The 12 supplemented PRE ions are shown in Table 1. The correlation of all NL and PRE scans were visualized in Fig. 11.

Figure 11. Correlation of all NL and PRE scans for metabolites identification of Scutellariae Radix.

Figure 11

Open in a new tab

Likewise, we established 14 new PRE scans for Puerariae Lobatae Radix and Coptidis Rhizoma (5S, 6S, and 7S). For example, magnoflorine (m/z 342) was found by the neutral loss scan of 45 Da. Its diagnostic signals m/z 342 and m/z 297 were used in successive PRE scans. A signal (RT = 14.0 min) was consistent in PRE 342, PRE 297 and NL176 scans, and was then identified as magnoflorine-O-GluA (CE5, confirmed by β-glucuronidase hydrolysis). As a result, in total 56, 47 and 31 metabolites were identified from Scutellariae Radix, Puerariae Lobatae Radix, and Coptidis Rhizoma, respectively (Tables 4S, 6S and 7S). Metabolites information of Glycyrrhizae Radix et Rhizoma Praeparata cum Melle were obtained from our previous study.

Metabolites identification of Gegen-Qinlian Decoction

Firstly, high-resolution mass spectrometry (HRMS) was employed to further confirm the formula of GQD metabolites. HRMS was performed using a qTOF-MS instrument. Mass error of all metabolites were not higher than 5 ppm, showing an agreement with the identified structure (Tables 4S, 6S, 7S). Then, a LC-SRM/MS method was established (Table 2, Table 8S) to detect 131 metabolites after oral administration of GQD (60 g/kg). Notably, when the dosage was reduced to approach clinical use (12.5 g/kg, equivalent to 6.26 g/kg of P, 2.34 g/kg of S and C, 1.56 g/kg of G), 112 metabolites could still be detected in rats plasma and urine samples. Source herb and in vivo distribution of these metabolites are shown in Table 9S. Thus far, the stepwise identification of GQD metabolites was achieved.

Table 2. Metabolites of Gegen-Qinlian Decoction identified in this study. Their retention time, SRM transitions, source herb, and distribution in biosamples.

No. tR (min) SRMa Identificationb Plasmac Urine Feces Herbd Reactione IDf Prodrugg
M1 8.5 479/125 pentahydroxyflavanone O-GluA / HL / S II Δ* S1
M2 8.8 534/358 monohydroxymagnoflorine O-GluA / HL / C I, II Δ C6
M3 9.4 479/125 pentahydroxyflavanone O-GluA / HL / S II Δ* S1
M4 9.6 534/358 monohydroxymagnoflorine O-GluA / HL / C I, II Δ C6
M5 11.5 477/125 pentahydroxyflavonol O-GluA / H / S II Δ* S6
M6 11.7 591/415 puerarin O-GluA HL HL / P II Δ* P9
M7 11.9 607/431 3′-hydroxypuerarin O-GluA HL HL / P II Δ* P10
M8 12.5 431/311 3′-hydroxypuerarin / HL H P NA * P10
M9 12.8 548/372 3′-methoxypuerarin O-GluA / HL / C II Δ P2
M10 12.8 621/445 3′-methoxypuerarin O-GluA HL HL / P II Δ* P2
M11 12.9 479/125 pentahydroxyflavanone O-GluA / HL / S II Δ* S1
M12 13.2 534/358 monohydroxymagnoflorine O-GluA / HL / C II Δ C6
M13 13.8 495/415 puerarin O-Sul HL HL / P II Δ* P9
M14 14.0 518/342 3′-methoxypuerarin O-Sul HL HL / C II Δ* P2
M15 14.0 525/445 magnoflorine O-GluA / HL / P II Δ* C6
M16 14.1 593/417 3′-hydroxypuerarin O-Sul / HL / G II Δ* P10
M17 14.1 511/431 liquiritin 7-O-GluA HL HL / P II Δ* G1
M18 14.6 484/308 didemethylepiberberine O-GluA / HL / C II Δ C3
M19 15.5 342/297 magnoflorine HL HL / C NA * C6
M20 15.6 415/295 puerarin HL HL H P NA * P9
M21 15.8 660/308 didemethylberberine di-O-GluA HL HL / C II Δ C2
M22 16.6 509/333 daidzein O-Sul-O-GluA HL HL / P II Δ* P3
M23 16.9 547/295 mirificin HL HL H P NA * P11
M24 17.0 445/325 3′-methoxypuerarin HL HL H P NA * P2
M25 17.1 525/325 methoxypuerarin O-Sul HL / / P I, II Δ P9
M26 17.7 577/325 3′-methoxymirificin HL HL / P NA * P13
M27 18.0 548/372 methoxymagnoflorine O-GluA / HL / C II Δ C6
M28 19.5 445/325 methoxypuerarin HL HL / P I   P9
M29 20.6 429/253 daidzein O-GluA HL HL / P II Δ* P3
M30 20.9 500/324 demethyleneberberine O-GluA / HL / C II Δ* C8
M31 21.4 498/322 thalifendine 10-O-GluA HL H / C II Δ  
M32 21.6 514/338 3-methoxydemethyleneberberine 2-O-GluA HL HL / C I, II Δ C8
M33 22.6 601/425 viscidulin III O-GluA-O-Sul HL HL / S II Δ* S7
M34 23.0 577/457 chrysin 6,8-di-C-glucoside H / / S NA    
M35 24.7 511/335 liquiritigenin O-GluA-O-Sul HL / / G II Δ* G10
M36 24.9 498/322 berberrubine 9-O-GluA HL HL / C II Δ* C7
M37 25.8 473/297 puerol A O-GluA HL HL / P II Δ* P15
M38 25.8 521/345 viscidulin III O-GluA / H / S II Δ* S7
M39 27.1 322/307 groenlandicine HL HL / C NA    
M40 27.6 324/309 demethyleneberberine / H / C NA * C8
M41 27.8 549/255 liquiritin apioside H H / G NA * G4
M42 28.1 417/255 liquiritin H HL / G NA * G1
M43 28.2 431/175 liquiritigenin O-GluA / HL / G II Δ* G10
M44 28.2 513/337 davidigenin O-GluA-O-Sul HL / / G I, II Δ* G9
M45 28.2 547/427 chrysin 6-C-Ara-8-C-Glc HL HL / S NA * S4
M46 28.5 605/429 4′-methoxypuerarin 7-O-GluA HL H / P II Δ* P14
M47 29.5 431/175 liquiritigenin O-GluA HL HL / G II Δ* G10
M48 30.8 497/241 equol O-Sul-O-GluA HL / / P I, II Δ* P5
M49 31.4 521/345 viscidulin III O-GluA HL / / S II Δ* S7
M50 31.9 497/241 equol O-Sul-O-GluA HL / / P I, II Δ* P5
M51 32.0 473/297 puerol A O-GluA HL HL / P II Δ* P15
M52 32.0 445/269 3′-hydroxydaidzein O-GluA HL HL / P II Δ* P17
M53 32.0 605/253 chrysin di-O-GluA HL HL / S II Δ* S8
M54 32.5 547/427 isomer of chrysin 6-C-Ara-8-C-Glc HL HL / S NA    
M55 35.3 429/309 4′-methoxypuerarin HL HL H P NA * P14
M56 35.8 561/309 formonetin 8-C-glu(6-1)-Api HL HL / P NA * P6
M57 36.8 497/241 equol O-Sul-O-GluA HL / / P I, II Δ* P5
M58 36.9 320/292 coptisine HL / H C NA * C5
M59 37.2 338/323 demethyleneberberine HL HL H C I * C8
M60 37.2 336/321 epiberberine HL HL H C NA * C3
M61 37.6 322/307 thalifendine / HL / C NA    
M62 38.7 338/323 jatrorrhizine HL HL H C NA * C4
M63 39.4 607/431 baicalein 7-O-Glc-O-GluA HL HL / S II Δ* S9
M64 40.1 621/445 baicalein di-O-GluA HL HL / S II Δ* S16
M65 40.2 459/283 3′-methoxydaidzein O-GluA HL H / P II Δ* P18
M66 41.1 417/241 equol O-GluA HL HL / P I, II Δ* P5
M67 42.3 513/337 davidigenin O-GluA-O-Sul HL / / G I, II Δ* G9
M68 43.5 635/459 wogonin di-O-GluA HL HL / S II Δ* S2
M69 43.6 377/297 puerol A O-Sul / HL / P II Δ* P15
M70 44.0 577/401 apigenin-8-C-Ara O-GluA HL HL / S II Δ  
M71 44.1 333/253 chrysin 6-C-Ara O-GluA H HL / P II Δ  
M72 44.1 561/385 daidzein O-Sul H / / S II Δ* P3
M73 45.3 363/283 3′-methoxydaidzein O-Sul HL HL / P II Δ* P18
M74 45.8 363/283 3′-methoxydaidzein O-Sul HL HL / P II Δ* P18
M75 49.5 336/321 berberine HL HL H C NA * C2
M76 50.4 297/119 puerol A / HL / P NA * P15
M77 50.7 345/315 viscidulin III / H / S NA * S7
M78 52.1 352/337 palmatine HL HL H C NA * C1
M79 53.2 443/267 formononetin O-GluA HL HL / P II Δ* P20
M80 53.4 487/311 puerol B O-GluA HL HL / P II Δ* P16
M81 54.2 445/269 baicalin / HL / S NA * S10
M82 54.6 525/445 norwogonin O-Sul HL HL / S II Δ  
M83 55.7 433/257 davidigenin O-GluA / H / G I, II Δ* G9
M84 55.9 255/119 dihydrodaidzein H HL / P I * P19
M85 56.0 487/311 puerol B O-GluA HL / / P II Δ* P16
M86 56.3 253/225 daidzein HL HL H P NA * P3
M87 56.3 509/253 chrysin O-GluA-O-Sul / H / S II Δ* S8
M88 57.0 433/257 O-desmethylangolensin O-GluA HL HL / P I, II Δ* P7
M89 57.0 385/295 chrysin 6-C-Ara / HL / S NA    
M90 57.1 283/268 3′-methoxydaidzein HL HL / P NA * P18
M91 57.2 459/283 wogonin 5-O-GluA HL H / S II Δ* S2
M92 57.7 555/475 lateriflorein 7-O-GluA-O-Sul HL / / S II Δ S11
M93 57.8 525/269 norwogonin O-Sul / H / S II Δ  
M94 57.9 445/269 norwogonin 7-O-GluA / HL / S NA * S12
M95 58.0 429/253 chrysin 7-O-GluA H / / S NA * S5
M96 58.0 539/283 oroxylin A 7-O-GluA-O-Sul HL HL / S II Δ* S14
M97 58.4 511/431 baicalein O-Glc-O-Sul H H / S II Δ  
M98 58.5 337/257 O-desmethylangolensin O-Sul HL HL / P I, II Δ* P7
M99 58.7 321/241 equol O-Sul HL / / P I, II Δ* P5
M100 58.8 445/269 norwogonin O-GluA HL HL H S II Δ  
M101 58.9 447/271 naringenin O-GluA HL H / G II Δ* G14
M102 58.9 525/269 baicalein O-GluA-O-Sul HL / / S II Δ* S16
M103 59.0 425/345 viscidulin III O-Sul H H, L / S II Δ* S7
M104 59.2 459/283 oroxylin A 7-O-GluA HL H / S NA * S14
M105 59.4 475/299 lateriflorein 7-O-GluA HL HL / S NA * S11
M106 59.6 431/269 baicalein O-glc / HL / S NA * S9
M107 59.7 705/529 licoisoflavone A di-O-GluA H / / G II Δ* G13
M108 59.9 445/269 baicalein O-GluA HL HL H S II Δ* S16
M109 60.2 481/401 apigenin-8-C-Ara O-Sul HL HL / S II Δ  
M110 60.3 459/283 wogonoside HL H / S NA * S15
M111 61.6 337/257 davidigenin O-Sul / HL / G I, II Δ* G9
M112 61.8 515/339 licocoumarone O-GluA HL / / G II Δ* G12
M113 62.0 391/311 puerol B O-Sul HL HL / P II Δ* P16
M114 62.2 271/151 naringenin / HL / G NA * G14
M115 63.3 311/119 puerol B H HL H P NA * P16
M116 63.7 337/257 davidigenin O-Sul / HL / G II Δ* G9
M117 63.9 299/284 lateriflorein / H / S NA    
M118 64.2 837/351 licorice-saponin G2 H / / G NA * G7
M119 64.2 269/241 baicalein H HL / S NA * S16
M120 64.6 257/151 davidigenin H HL / G I * G9
M121 65.4 257/135 O-desmethylangolensin / HL / P I * P7
M122 65.6 821/351 glycyrrhizic acid H / / G NA * G6
M123 66.2 267/252 formononetin H HL H P NA * P20
M124 66.3 269/254 dihydrofomononetin H HL / G I   P20
M125 66.9 347/267 formononetin O-Sul HL HL / P II Δ* P20
M126 69.6 283/268 wogonin HL HL H S NA * S2
M127 69.8 253/151 chrysin / H / S NA * S8
M128 70.7 367/309 glycycoumarin H H H G NA * G11
M129 70.7 283/268 oroxylin A HL HL H S NA * S3
M130 73.5 365/307 glycyrol HL HL H G NA * G15
M131 77.6 469/425 glycyrrhetinic acid H / / G NA * G16
Open in a new tab

aSRM, metabolites derived from Coptidis Rhizoma were monitored in (+) ESI. Other SRM transitions were detected in (−) ESI, see Table 8S.

bIdentification: Api, apioside; Ara, arabicoside; GluA, glucuronide; Glc, glucoside; Sul, sulfate.

cDistribution, H, detected in high-dose treated biosamples; L, detected in low-dose treated biosamples; /, not detected.

dComponent herb to produce corresponding analyte. P, Puerariae Lobatae Radix; S, Scutellariae Radix; C, Coptidis Rhizoma; G, Glycyrrhizae Radix et Rhizoma Praeparata cum Melle.

eMetabolic reaction: NA, compound was detected as prototype, I, phase I reaction; II, phase II reaction; I, II, multiple reactions.

fID, *, identified by comparing with reference standards; Δ, confirmed as phase II metabolites by β-glucuronidase hydrolysis; Δ*, confirmed as phase II metabolites by β-glucuronidase hydrolysis, and the aglycone was identified by comparing with reference standards.

gProdrug, proposed parent molecule of the metabolites.

Discussion

In vivo metabolites of natural products have comparative, even favorable chances to initiate therapeutic effects as the unchanged form. Therefore, we established the new strategy “compound to extract to formulation”, which could be used to systematically identify the metabolites of Chinese medicine formulas. Although a number of reports are available on metabolites identification of Chinese medicine formulas, most of the studies directly characterized the metabolites by LC/MS techniques. Structural characterization of the metabolites may not be solid enough due to limited structural information provided by mass spectrometry. In our work, the metabolites were not only identified by mass spectrometry, but also according to the metabolic rules of different types of compounds. The metabolites of the formula were also compared with those of single component herbs.

To the specific formulation GQD, we had identified 42 metabolites using LC/MS techniques19. We had also established a “Compound to Extract” strategy to discover the metabolites in licorice, one component herb in GQD20. However, the complexity of GQD was not fully represented, given that at least 138 compounds could be identified in GQD by 2D-LC/MS. Thus, the metabolic pathways of other representative compounds should be investigated to comprehensively identify the metabolites of GQD. Therefore, we established the knowledge-transmitting approach addressing the complexity of this four-herb formulation. The strategy contains the following steps:

  1. Background knowledge of the target TCM formulation. We use the information to divide the formula into 8 chemical groups (A to G), and to select representative single compounds.

  2. Metabolite identification of 19 single compounds. Metabolites (in rats plasma, urine and feces) were identified by the aid of UV spectra, HPLC retention, tandem MS, β-glucuronidase hydrolysis, and comparison with reference standards. MS fragmentation pattern were also revealed in this step. We proposed the metabolic routes (as in Figs 4, 6 and 1S) and obtained 57 diagnostic NL/PRE ions (22, 21 and 18 for P, S, and C, respectively, as in Figs 5, 7 and 8).

  3. Metabolites screening for herbal extracts. NL/PRE scans were used to confirm known fragments and to exhume unpredicted metabolites (Fig. 9). The process (Fig. 10) established 8, 18 and 8 NL/PRE channels for P, S, and C, respectively. Metabolites were identified by matching the screening data in NL and PRE modes. SRM transitions of the metabolites were obtained. The metabolic fate of chemically different compounds were summarized in Table 1.

  4. Monitoring the metabolites for the four-herb formula. The metabolites were confirmed by HRMS, and were monitored in rats plasma by LC-SRM/MS (Table 2). In total 131 metabolites were detected at a high (60 g/kg) dose, including 46 phytochemicals and 85 newly formed ones. Among them, 112 metabolites could be detected in clinical (12.5 g/kg) dosage.

Different from most metabolite identification reports, the metabolic routes for different scaffolds in GQD were addressed, and the information was transferred from compound to formula with less loss or redundancy. Moreover, parent compounds for the detected metabolites were interpreted. On the other hand, background knowledge for chemical constituents in the formulation was required to use this strategy, which might be less convenient for extracts whose components were unknown.

The strategy allowed systematic discovery of GQD metabolites. In our previous study, 42 metabolites could be identified by LC/MSn for Gegen-Qinlian-Wan, following a high dose of administration (66.6 g/kg). Detectable metabolites could be fewer than 20 using a clinical dose. In the current study, 131 metabolites were identified following the knowledge-transmitting strategy. Among them, 36 were identified by comparison with authentic references, and 81 could be identified after β-glucuronidase hydrolysis (45 compared with reference standards). Particularly, in vivo exposure of Pueraria puerosides and Scutellaria pentahydroxyflavanones had yet to be reported, and they were revealed by using our NL/PRE metabolic screening method. In total 34 metabolites were unchanged constituents from GQD, as shown in Table 2. These compounds could be important to the pharmacological effect of GQD.

The “Compound to Extract to Formulation” strategy also provided reliable and traceable metabolites identification. For a metabolite, the strategy could be helpful to trace back to its source herb and source compound. For instance, in the plasma of GQD-treated rats, two metabolites were detected by the SRM pair m/z 429 > 253 (Fig. 12). Compared with the component herbs, the metabolites were derived from Puerariae Lobatae Radix (RT = 20.6 min, M29) and Scutellariae Radix (RT = 58.0 min, M95), respectively. In succession, Scutellariae Radix-treated rats plasma were hydrolyzed by β-glucuronidase, and the aglycone of M95 was identified as chrysin. Based on the chemistry of Scutellariae Radix13, chrysin backbone was involved in three types of constituents, including flavonoid di-C-glycosides (represented by S4), chrysin 7-O-GluA (S5), and chrysin (S8). Based on the knowledge from single compounds, de-conjugation of the C-arabinoside was difficult in vivo, thus S4 was less possible to be the parent compound of M95. Meanwhile, S5 could be absorbed and exposed in plasma, while chrysin (S8) could be easily transformed into its glucuronide-conjugated from. Finally, the metabolic route for M95 is elucidated in Fig. 12. Similarly, the 131 metabolites of GQD could be tracked back to 52 parent phytochemicals. These compounds were listed in Table 2.

Figure 12. A trace back from metabolite M95 to its parent compounds in GQD.

Figure 12

Open in a new tab

Experimental

Materials and reagents

HPLC grade acetonitrile and formic acid (J. T. Baker, Phillipsburg, NJ) were used for LC/MS analysis. De-ionized water was purified by a Milli-Q system (Millipore, Bedford, MA). Other solvents were of analytical grade. Daidzin (P1), 3′-methoxypuerarin (P2), daidzein (P3), ononin (P4), formononetin 8-C-apiofuranosyl(1,6)glucoside (P6), 3′-methoxydaidzin (P8), puerarin (P9), 3′-hydroxypuerarin (P10), mirificin (P11), (4S)-puerol B-2′′-O-glucopyranoside (P12), 3′-methoxymirificin (P13), 4′-methoxypuerarin (P14), 3′-hydroxydaidzein (P17), 3′-methoxydaidzein (P18), dihydrodaidzein (P19), and formononetin (P20) were isolated from Puerariae Lobatae Radix. (2R,3R)-3,5,7,2′,6′-Pentahydroxyflavanone (S1), wogonin (S2), oroxylin A (S3), chrysin 6-C-arabinoside-8-C-glucoside (S4), chrysin 7-O-glucuronide (S5), 3,5,7,2′,6′-pentahydroxyflavonol (S6), chrysin (S8), baicalein 7-O-glucoside (S9), baicalein (S10), lateriflorein 7-O-glucuronide (S11), norwogonin 7-O-glucuronide (S12), oroxylin A 7-O-glucuronide (S14), wogonoside (S15), baicalin (S16), and acteoside (S17) were isolated from Scutellariae Radix. Liquiritin (G1), isoliquiritin (G2), 7,4-dihydroxyflavone (G3), liquiritin apioside (G4), isoliquiritin apioside (G5), glycyrrhizic acid (G6), licorice saponin G2 (G7), isoliquiritigenin (G8), liquiritigenin (G10), glycycoumarin (G11), licocoumarone (G12), licoisoflavone A (G13), glycyrol (G15), and isoangustone A (G17) were isolated from Glycyrrhizae Radix. All the above compounds were purified by the authors, and the structures were identified by UV, MS, and NMR spectroscopic analyses. Palmatine (C1), berberine (C2), epiberberine (C3), jatrorrhizine (C4), coptisine (C5), magnoflorine (C6), and scutellarin (S13) were purchased from Mansite Bio-Technology Co., Ltd. (Chengdu, China). Demethyleneberberine (C8) was from Feiyu Fine Chemical (Jiangsu, China). Berberrubine (C7), naringenin (G14) and glycyrrhetinic acid (G16) were purchased from Zelang Co. Ltd. (Nanjing, China). Viscidulin III (S7) was purchased from BioBioPha Co. Ltd (Yunnan, China). Puerol A (P15) and puerol B (P16) were obtained by hydrolysis of (4S)-puerol A 2′′-O-glucopyranoside and (4S)-puerol B-2′′-O-glucopyranoside (P12) (isolated from P), respectively. Davidigenin (G9) was synthesized as previously reported21. O-Desmethylangolensin (P7) was kindly donated by Professor Xiu-ling Wang at Hebei Agricultural University. S-Equol (P5) and β-glucuronidase (HP-2 type) were purchased from Sigma-Aldrich (St. Louis, MO). All the above reference compounds showed purities of >98% by HPLC/UV analysis. Their structures are given in Fig. 3.

Puerariae Lobatae Radix (P), Scutellariae Radix (S), Coptidis Rhizoma (C), and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle (G) were purchased from TianHeng pharmacy (Beijing, China). They were identified as dried roots of Pueraria lobata (Willd.) Ohwi, dried roots of Scutellaria baicalensis Georgi, dried rhizomes of Coptis chinensis Franch., and dried roots and rhizomes of Glycyrrhiza uralensis Fisch. (stir-baked with honey), respectively, according to the Chinese Pharmacopeia (2015 edition)10. GQD decoction was prepared according to its original record in Shang-Han-Lun. The four crude drug materials (slices) were separately decocted in 10-fold volume of water for three times (1.5 h, 1.5 h, 0.5 h) to obtain the extracts. GQD was prepared by extracting the four component herbs (P:S:C:G = 8:3:3:2) using the same method as described above for the single herbs, after a pre-extraction of Puerariae Lobatae Radix for 0.5 h. For each extract, the decoctions were filtered to remove the herbal residue, combined, and concentrated in vacuum at 50 °C. Final concentrations of the extracts were 0.8 g/mL for Puerariae Lobatae Radix, 1.5 g/mL for Scutellariae Radix, 0.75 g/mL for Coptidis Rhizoma, and 1.6 g/mL for GQD (crude drug per g/mL).

Animals

Male Sprague-Dawley rats (8–10 weeks, 180–250 g) were provided by Experimental Animal Center of Peking University Health Science Center (Beijing, China). The rats were kept in a controlled environment at 25 °C, 60 ± 5% humidity and a 12-h dark-light cycle for 10 days, with free access to water and normal diet. Animals treated with Pueraria compounds, Puerariae Lobatae Radix, and GQD were fed with soy-free custom diet (Ke’ao Xieli Co., Beijing, China) to avoid disturbance of isoflavones in soybean23. All animals were fasted for 12 h before treatment. The animal facilities and protocols were approved by the Animal Care and Use Committee of Peking University Health Science Center. All procedures were in accordance with Guide for the Care and Use of Laboratory Animals (National Institutes of Health).

All single compounds were dissolved or suspended in 0.03% carboxymethylcellulose sodium salt solution, and were then orally administered to rats (40 mg/kg). Herbal extracts were administrated separately at two doses, 1.2 and 16 g/kg for Puerariae Lobatae Radix, 0.6 and 6 g/kg for Scutellariae Radix, 0.5 and 6 g/kg for Coptidis Rhizoma, and 12.5 and 60 g/kg for GQD (crude drug per g/kg of body weight), respectively. Dosage ratio among component drugs followed their composition in GQD, and the high dosages are roughly 10 folds of low ones (13, 10 and 12 folds for P, S, C), respectively. Medication groups received 4.0, 0.8, 1.6 and 7.5 mL decoction of Pueraria, Scutellaria, Coptidis, and GQD, respectively. The control group received 2 mL of normal saline.

Retro-orbital blood (400 μL) were collected into heparinized tubes at 0.25, 0.5, 1.5, 4, 6, 8 and 12 h after administration (n = 2). Blood samples were immediately centrifuged at 6000 rpm (4 °C) for 20 min. The supernatant was separated and combined as pooled plasma samples. Urine and feces samples were collected over 0–12 h and 12–24 h periods (n = 2), and then combined. All samples were stored at −20 °C until analysis.

Sample preparation

Plasma (pooled) – 4 mL of plasma was mixed with 12 mL of methanol. The mixture was vortexed at 2200 rpm for 5 min, and then centrifuged (9000 rpm, 4 °C) for 10 min. The supernatant was separated and dried under a gentle flow of nitrogen at 40 °C. Urine (pooled) – 4 mL of urine was centrifuged (9000 rpm, 4 °C, 5 min) and loaded onto an Oasis® HLB SPE column (6 cc, pre-eluted with 6 mL of methanol and 6 mL of de-ionized water, successively). The samples were eluted with 3 mL of de-ionized water, 3 mL of 5% methanol, and 5 mL of methanol in succession. The methanol fraction was collected and dried under a gentle flow of nitrogen at 40 °C. Feces (pooled) – 0.5 g of dried sample was extracted with 10 mL of methanol in an ultrasonic bath for 30 min, and centrifuged (9000 rpm, 4 °C) for 10 min. The supernatant was collected and dried under a gentle flow of nitrogen at 40 °C. Residues of plasma, urine and feces were stored at −20 °C until use. Samples were reconstituted and diluted differently according to analytical method, which was described as follows. All samples were filtered through a 0.22-μm membrane. The combination of different pre-treatment, separation and detection methods was summarized in Table 3.

  1. Samples from single-compound administrated animals were reconstituted in 500 μL of methanol before analysis.

  2. Samples from herbal extract administrated animals were reconstituted in 500 μL of methanol, and then diluted for 5, 5, and 10 folds (for plasma, urine and feces samples).

  3. Samples from single-compound administrated animals were reconstituted in 1000 μL of methanol before analysis.

Table 3. Application of different analytical methods for single compounds, herbal extracts and TCM formulation.

  Sample preparation Liquid chromatographya Mass spectrometryb
Single compound a (Section I) HPLC (Section II) a 2.1 × 150 mm, 3.5 μm MSn (Section III), NL, PRE (Section IV)
Herbal extract b (Section I) HPLC (Section II) b 4.6 × 250 mm, 5 μm NL, PRE (Section IV)
TCM formulation c (Section I) HPLC (Section II) b 4.6 × 250 mm, 5 μm SRM (Section IV)
    UHPLC (Section V) 2.1 × 100 mm, 1.8 μm Full Scan, MS/MS (Section V)
Open in a new tab

aMethod applied were described in different sections (section I: Sample preparation; section II: HPLC analysis; section III: Tandem mass spectrometry; section IV: Neutral loss scan, precursor ion scan, and SRM scan; section V: UHPLC-DAD-qTOF-MS analysis).

bMSn, tandem mass spectrometry; NL, neutral loss scan; PRE, precursor ion scan; SRM, selected reaction monitoring.

Enzyme hydrolysis

The structures of glucuronides were confirmed by enzyme hydrolysis. The plasma or urine sample (50 μL) described under “Sample preparation” section was dried under nitrogen flow (40 °C) and mixed with 200 μL of β-glucuronidase solution (containing 19.86 U, in sodium acetate buffer, pH 5.5). The mixture was vortexed at 2200 rpm for 5 min, incubated at 37 °C for 2 h, mixed with 800 μL of methanol, and prepared using the same method as plasma samples as described in “Sample preparation” section. The residue was reconstituted in 300 μL of methanol before analysis.

HPLC analysis

A Finnigan Surveyor LC instrument was employed (ThermoFisher, CA, USA). The mobile phase consisted of acetonitrile (A) and water containing 0.1% formic acid (B).

  1. An Atlantis T3 column (3 μm, ID 2.1 × 150 mm) equipped with an XTerra MS C18 guard column (5 μm, ID 3.9 × 20 mm) (Waters, MA, USA) was used. The gradient elution program was used as follows: 0–8 min, 5–25% A; 8–12 min, 25% A; 12–15 min, 25–40% A; 15–23 min, 40–80% A; 23–25 min, 80–95% A; 25–27 min, 95% A. The flow rate was 200 μL/min. The HPLC effluent was introduced into the mass spectrometer without splitting. The column temperature was 30 °C. An aliquot of 5 μL was injected for analysis.

  2. An Agilent Eclipse XDB C18 column (5 μm, 4.6 × 250 mm) equipped with a Zorbax SB C18 guard column (5 μm, 4.6 × 12.5 mm) was used. The gradient elution program was as follows: 0–10 min, 5–12% A; 10–40 min, 12–19% A; 40–50 min, 19–20% A; 50–70 min, 20–55% A; 70–75 min, 55–90% A; 75–80 min, 90–100% A. The flow rate was 1000 μL/min. The column temperature was 30 °C. The post-column splitting ratio was 3:1. An aliquot of 10 μL was injected.

Tandem mass spectrometry

A Finnigan LCQ Advantage ion trap mass spectrometer equipped with an ESI interface (Thermo Finnigan, San Jose, CA, USA) was used. Collision gas, high purity helium (He); nebulizing gas, high purity nitrogen (N2). Source-dependent parameters were as follows: sheath gas (N2), 50 arb; auxiliary gas (N2), 15 arb; spray voltage, 4.5 kV; capillary temperature, 330 °C; capillary voltage, 3 V/−4 V (positive/negative mode); tube lens offset voltage, 30 V/−60 V (positive/negative mode). MS full scan range, m/z 120–1500; Collision energy for CID, 35%; Source-fragmentation voltage, 0 V/25 V (positive/negative mode).

Neutral loss scan, precursor ion scan, and SRM scan

A Finnigan TSQ Quantum triple quadrupole mass spectrometer was connected to the HPLC via ESI interface (ThermoFisher, CA, USA). The mass spectrometer was operated in the negative and positive ion modes. High purity nitrogen was used as the sheath and auxiliary gas; high purity argon was used as the collision gas (1.5 mTorr). Q1 and Q3 quadrupoles were set at unit resolution. Tune parameters and NL/PRE ions were described in Table 5S.

UHPLC-DAD-qTOF-MS analysis

An Agilent series 1290 UHPLC instrument (Agilent, Waldbronn, Germany) was coupled with a 6538 qTOF mass spectrometer (Agilent Technologies, Santa Clara, CA) via an ESI interface. The UHPLC instrument was equipped with a binary pump, a diode-array detector, an autosampler, and a column compartment. Samples were separated on a Zorbax Eclipse Plus C18 column (2.1 × 100 cm, 1.8 μm). The mobile phase consisted of acetonitrile (A) and water containing 0.1% (v/v) formic acid (B). A gradient program was used as follows: 0–10 min, 10–30% A; 10–15 min, 30–50% A; 15–20 min, 50–80% A; 20–22 min, 80–95% A; 22–24 min, 95% A; 24–30 min, 10% A. Flow rate, 300 μL/min; column temperature, 40 °C; injection volume, 2 μL. High-purity nitrogen (N2) was used as drying gas (10 mL/min) and nebulizing gas (45 psig), and ultra-high purity helium (He) was used as the collision gas. Both negative and positive ion polarity modes were used for compounds ionization. Gas temperature was 350 °C. Other parameters were as follows: capillary voltage, 4000 V; fragmentor voltage, 130 V; skimmer voltage, 65 V; octopole 1 rf voltage, 750 V; data acquisition, 2 spectra/s. Mass spectra were recorded in the range of m/z 150–1000. MSn (n = 2–4) was triggered by a data-dependent threshold. Data were analyzed with MassHunter software (Agilent Technologies).

Conclusions

A knowledge-transmitting approach was established to elucidate in vivo metabolites of Gegen-Qinlian Decoction. The metabolites of GQD was revealed stepwise, from single compounds to component herb, and then to the formulation. The study improved previous ones in the following points: (i) 85 newly formed metabolites were identified and monitored unbiasly; (ii) metabolic fate of different structural types (classified as 8 groups) were revealed globally; and (iii) metabolites could be tracked back to 52 parent phytochemicals. The knowledge-transmitting strategy helped us to analyse in vivo metabolites systematically, toward a very complex TCM formulation. Knowledge of these metabolites will be valuable for elucidating the mechanism of action of Gegen-Qinlian Decoction.

Additional Information

How to cite this article: Qiao, X. et al. Compound to Extract to Formulation: a knowledge-transmitting approach for metabolites identification of Gegen-Qinlian Decoction, a traditional Chinese medicine formula. Sci. Rep. 6, 39534; doi: 10.1038/srep39534 (2016).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Material

Supporting Information
srep39534-s1.pdf (319.3KB, pdf)

Acknowledgments

This work was supported by National Natural Science Foundation of China (No. 81173644, No. 81222054), and the Program for New Century Excellent Talents in University from Chinese Ministry of Education (No. NCET-11-0019). We thank Dr. Zheng-xiang Zhang and Dr. Tao Bo (Agilent Technologies) for their technical help in LC/MS analysis.

Footnotes

Author Contributions M. Ye and X. Qiao participated in research design. X. Qiao, Q. Wang, S. Wang, W. Miao and Y. Li conducted the experiments. M. Ye, X. Qiao, W. Miao and C. Xiang performed data analysis. M. Ye., X. Qiao, S. Wang and D. Guo contributed to the writing of the manuscript.

References

  1. Tian P. Where west meets east. Nature 480, S84–S86 (2011). [DOI] [PubMed] [Google Scholar]
  2. Lachance H., Wetzel S., Kumar K. & Waldmann H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem. 55, 5989–6001 (2012). [DOI] [PubMed] [Google Scholar]
  3. Beekmann K. et al. A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids. Food Funct. 3, 1008–1018 (2012). [DOI] [PubMed] [Google Scholar]
  4. Prasad B., Garg A., Takwani H. & Singh S. Metabolite identification by liquid chromatography-mass spectrometry. TrAC-Trend Anal. Chem. 30, 360–387 (2011). [Google Scholar]
  5. Xin G.-Z. et al. Strategies for integral metabolism profile of multiple compounds in herbal medicines: pharmacokinetics, metabolites characterization and metabolic interactions. Curr. Drug Metab. 12, 809–817 (2011). [DOI] [PubMed] [Google Scholar]
  6. Li M. et al. Systemic exposure to and disposition of catechols derived from Salvia miltiorrhiza Roots (Danshen) after intravenous dosing DanHong injection in human subjects, rats, and dogs. Drug Metab. Dispos. 43, 679–690 (2015). [DOI] [PubMed] [Google Scholar]
  7. Wang X. J. et al. Pharmacokinetics screening for multi-components absorbed in the rat plasma after oral administration traditional Chinese medicine formula Yin-Chen-Hao-Tang by ultra performance liquid chromatography-electrospray ionization/quadrupole-time-of-flight mass spectrometry combined with pattern recognition methods. Analyst 136, 5068–5076 (2011). [DOI] [PubMed] [Google Scholar]
  8. Gong P. et al. Chemicalome and metabolome matching approach to elucidating biological metabolic networks of complex mixtures. Anal. Chem. 84, 2995–3002 (2012). [DOI] [PubMed] [Google Scholar]
  9. Chen Q., Xiao S., Li Z., Ai N. & Fan X. Chemical and metabolic profiling of Si-Ni decoction analogous formulae by high performance liquid chromatography-mass spectrometry. Sci. Rep-UK 5 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. State Commission of Chinese Pharmacopeia. In: Pharmacopoeia of People’s Republic of China Vol. I (ed. 2015), 1581–1583 (China Medical Science Press, 2015). [Google Scholar]
  11. Chen L. H., Tang Y. P. & Wang Q. Advances in studies on Gegen Qinlian Decoction. Chin. Trad. Herb. Drugs 41, 676–680 (2010). [Google Scholar]
  12. Niu Y. R. et al. Identification of isoflavonoids in Radix Puerariae for quality control using on-line high performance liquid chromatography-diode array detector-electrospray ionization-mass spectrometry coupled with post-column derivatization. Food Res. Int. 48, 528–537 (2012). [Google Scholar]
  13. Liu G. Z. et al. Investigation of flavonoid profile of Scutellaria bacalensis Georgi by high performance liquid chromatography with diode array detection and electrospray ion trap mass spectrometry. J. Chromatogr. A. 1216, 4809–4814 (2009). [DOI] [PubMed] [Google Scholar]
  14. Wang D. W., Liu Z. Q., Guo M. Q. & Liu S. Y. Structural elucidation and identification of alkaloids in Rhizoma Coptidis by electrospray ionization tandem mass spectrometry. J. Mass Spectrom. 39, 1356–1365 (2004). [DOI] [PubMed] [Google Scholar]
  15. Zhang Q. Y. & Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J. Chromatogr. A. 1216, 1954–1969 (2009). [DOI] [PubMed] [Google Scholar]
  16. Qiao X. et al. A chemical profiling solution for Chinese medicine formulas using comprehensive and loop-based multiple heart-cutting two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J. Chromatogr. A. 1438, 198–204 (2016). [DOI] [PubMed] [Google Scholar]
  17. Wang Q. et al. Simultaneous quantification of 50 bioactive compounds of the traditional Chinese medicine formula Gegen-Qinlian decoction using ultra-high performance liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. A. 1454, 15–25 (2016). [DOI] [PubMed] [Google Scholar]
  18. Yu C. P., Shia C. S., Tsai S. Y. & Hou Y. C. Pharmacokinetics and relative bioavailability of flavonoids between two dosage forms of Gegen-Qinlian-Tang in rats. Evid.-based Complement Altern. Med. 2012, 1325 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Miao W. J. et al. Rapid characterization of chemical constituents and rats metabolites of the traditional Chinese patent medicine Gegen-Qinlian-Wan by UHPLC/DAD/qTOF-MS. J. Pharm. Biomed. Anal. 72, 99–108 (2013). [DOI] [PubMed] [Google Scholar]
  20. Xiang C. et al. From Single Compounds to Herbal Extract: A strategy to systematically characterize the metabolites of licorice in rats. Drug Metab. Dispos. 39, 1597–1608 (2011). [DOI] [PubMed] [Google Scholar]
  21. Qiao X. et al. Analytical strategy to reveal the in vivo process of multi-component herbal medicine: A pharmacokinetic study of licorice using liquid chromatography coupled with triple quadrupole mass spectrometry. J. Chromatogr. A. 1258, 84–93 (2012). [DOI] [PubMed] [Google Scholar]
  22. Prasain J. K. et al. Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry. J. Agric. Food Chem. 52, 3708–3712 (2004). [DOI] [PubMed] [Google Scholar]
  23. Zhang Y., Tie X. W., Bao B. L., Wu X. Q. & Zhang Y. Metabolism of flavone C-glucosides and p-coumaric acid from antioxidant of bamboo leaves (AOB) in rats. Br. J. Nutr. 97, 484–494 (2007). [DOI] [PubMed] [Google Scholar]
  24. Hosoda K., Furuta T., Yokokawa A. & Ishii K. Identification and quantification of daidzein-7-glucuronide-4′-sulfate, genistein-7-glucuronide-4′-sulfate and genistein-4′,7-diglucuronide as major metabolites in human plasma after administration of kinako. Anal. Bioanal. Chem. 397, 1563–1572 (2010). [DOI] [PubMed] [Google Scholar]
  25. Lee J. S., Kim D. H., Liu K. H., Oh T. K. & Lee C. H. Identification of flavonoids using liquid chromatography with electrospray ionization and ion trap tandem mass spectrometry with an MS/MS library. Rapid Commun. Mass Spectrom. 19, 3539–3548 (2005). [DOI] [PubMed] [Google Scholar]
  26. Liu Q. F. et al. Metabolism profile of scutellarin in urine following oral administration to rats by ultra performance liquid chromatography coupled to time-of-flight mass spectrometry. Talanta. 80, 84–91 (2009). [DOI] [PubMed] [Google Scholar]
  27. Li C. R., Zhang L., Lin G. & Zuo Z. Identification and quantification of baicalein, wogonin, oroxylin A and their major glucuronide conjugated metabolites in rat plasma after oral administration of Radix scutellariae product. J. Pharm. Biomed. Anal. 54, 750–758 (2011). [DOI] [PubMed] [Google Scholar]
  28. Chen X. Y., Cui L., Duan X. T., Ma B. & Zhong D. F. Pharmacokinetics and metabolism of the flavonoid scutellarin in humans after a single oral administration. Drug Metab. Dispos. 34, 1345–1352 (2006). [DOI] [PubMed] [Google Scholar]
  29. Abe K., Inoue O. & Yumioka E. Biliary-excretion of metabolites of baicalin and baicalein in rats. Chem. Pharm. Bull. 38, 208–211 (1990). [PubMed] [Google Scholar]
  30. Matern H., Matern S. & Gerok W. Formation of bile-acid glucosides by a sugar nucleotide-independent glucosyltransferase isolated from human-liver microsomes. Proc. Natl. Acad. Sci. USA 81, 7036–7040 (1984). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Ye M. et al. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Commun. Mass Spectrom. 21, 3593–3607 (2007). [DOI] [PubMed] [Google Scholar]
  32. Yang Y. H. et al. Metabolites of protoberberine alkaloids in human urine following oral administration of coptidis rhizoma decoction. Planta Med. 76, 1859–1863 (2010). [DOI] [PubMed] [Google Scholar]
  33. Qiu F. et al. Isolation and identification of urinary metabolites of berberine in rats and humans. Drug Metab. Dispos. 36, 2159–2165 (2008). [DOI] [PubMed] [Google Scholar]
  34. Zhu M. M., Han F. M., Chen H. X., Peng Z. H. & Chen Y. Identification of palmatine and its metabolites in rat urine by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 21, 2019–2022 (2007). [DOI] [PubMed] [Google Scholar]
  35. Zhang Y., Wu W. H., Han F. M. & Chen Y. LC/MS/MS for identification of in vivo and in vitro metabolites of jatrorrhizine. Biomed. Chromatogr. 22, 1360–1367 (2008). [DOI] [PubMed] [Google Scholar]
  36. Liu Y. T. et al. Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats. Drug Metab. Dispos. 38, 1779–1784 (2010). [DOI] [PubMed] [Google Scholar]
  37. Heinonen S. M., Hoikkala A., Wahala K. & Adlercreutz H. Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J. Steroid Biochem. Mol. Biol. 87, 285–299 (2003). [DOI] [PubMed] [Google Scholar]
  38. Clarke N., Rindgen D., Korfmacher W. & Cox K. Systematic LC/MS metabolite identification in drug discovery. Anal. Chem. 73, 430A–439A (2001). [DOI] [PubMed] [Google Scholar]
  39. Ma S. G. & Chowdhury S. K. Analytical strategies for assessment of human metabolites in preclinical safety testing. Anal. Chem. 83, 5028–5036 (2011). [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information
srep39534-s1.pdf (319.3KB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES